TELA Bio Inc
NASDAQ:TELA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
TELA Bio Inc
NASDAQ:TELA
|
US |
TELA Bio Inc
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 123 full-time employees. The company went IPO on 2019-11-08. The firm is focused on designing, developing and marketing tissue reinforcement materials for soft tissue reconstruction. The company offers a portfolio of products and solutions for care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), is used for ventral hernia repair and abdominal wall reconstruction, inguinal hernia repair and hiatal hernia repair. Its OviTex PRS Reinforced Tissue Matrix (OviTex PRS) addresses needs in plastic and reconstructive surgery. Its OviTex PRS product is designed for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. Its subsidiary include TELA Bio Limited.
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 123 full-time employees. The company went IPO on 2019-11-08. The firm is focused on designing, developing and marketing tissue reinforcement materials for soft tissue reconstruction. The company offers a portfolio of products and solutions for care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), is used for ventral hernia repair and abdominal wall reconstruction, inguinal hernia repair and hiatal hernia repair. Its OviTex PRS Reinforced Tissue Matrix (OviTex PRS) addresses needs in plastic and reconstructive surgery. Its OviTex PRS product is designed for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. Its subsidiary include TELA Bio Limited.
Revenue: Q4 revenue was $20.9 million and full-year 2025 revenue was $80.3 million, up 18% YoY for Q4 and 16% for the year.
Commercial reset: Management completed a broad commercial rebuild in H2 2025, hiring to ~88 quota-carrying U.S. territory managers (target 76 exceeded) and restructuring territories, comp and leadership.
Guidance: 2026 revenue guidance is at least 8% growth over 2025 with Q1 revenue expected to be approximately $18.5 million; management set conservative cadence because many reps are early in ramp.
Unit trends: OviTex unit sales grew 20% in Q4 and 22% for the year; PRS unit sales grew 12% in both Q4 and full year; LIQUIFIX revenue more than tripled YoY in Q4.
Margins & losses: Gross margin improved to 66% in Q4 and 68% for the year; operating loss narrowed slightly (loss from operations $6.6M Q4, $33.8M FY) and net loss was $9.0M Q4 and $38.8M FY.
Europe & product mix: Europe contributed $12.1 million (15% of revenue) and grew 17% YoY; management highlighted mix shift toward smaller robotic/laparoscopic procedures (ingunials, LPR) affecting ASPs.
Execution focus: Management is prioritizing contract conversion and deeper penetration at high-volume sites (more users per hospital) rather than wide, shallow distribution.
